PIH22 Clinical Efficacy and Cost-Effectiveness of Human Recombinant Interferon-α2B in Neonatal Infections  by Soldatova, I. & Pankratyeva, L.
and gender, including physician visits, pain-clinic visits, neurology-clinic visits,
and ED visits. In the 75-84 years age group, frequency of utilization was higher by
22%, 39%, 45% and 48% for these health care resources, respectively.
CONCLUSIONS: Epidemiology of HZ in Israel is similar to that reported for other
countries. This illness presents a burden on the elderly population and is related
with increased resource utilization.
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COST BENEFIT ANALYSIS ON THE LONG TERM EFFECTS OF IN VITRO
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OBJECTIVES: To quantify the economic effects of an in-vitro-fertilization (IVF) born
persons in terms of productivity gains and net tax revenues for the state in Greece.
METHODS:A mathematical model was developed to assess the lifetime productiv-
ity and transactions between an individual and the governmental agencies. The
model distinguishes amongst three periods in economic life cycle: 1) early life,
when the government primarily contributes resources through child tax credits,
health care, and educational expenses; 2) employment, when individuals begin
returning resources through taxes; and 3) retirement, when the government ex-
pends additional resources on Social Security and old-age programs. Cost of life
birth with IVF was based on a modification of a previous published model devel-
oped by the authors. All outcomes were discounted at a 3% discounting rate. The
data inputs, namely the economic or demographic variables, were derived from
National Statistical Secretariat of Greece and other relevant sources. To deal with
uncertainty, bias corrected uncertainty intervals (UI) was calculated based on 5000
Monte Carlo simulations. In addition, to examine the robustness of our results,
other one-way sensitivity analyses were also employed. RESULTS: The cost of IVF
per birth was estimated at €17,078 (95%UI: €16,350-€17,805). The average projected
income generated by an individual throughout his productive life, was €667,651
(95%UI: €538,897-€762,862). In addition, his life tax contribution was estimated at
€200,295 (95%UI: €168,669-228,670), while the discounted governmental expenses
for elderly and underage individuals were at €36,570 (95%UI: €33,614-€40,463).
Hence, the net present value of IVF was €163,726 (95%UI: €124,533-€192,215) repre-
senting a 547% net return on investment. Results remained constant under various
assumptions for the main model parameters. CONCLUSIONS: State-funded IVF
represents good value for money in the Greek setting, as it has positive tax benefits
for the government, notwithstanding its beneficial psychological effect for infertil-
ity couples and the overall productivity gains.
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Infections are a major contributor to neonatal mortality and morbidity levels all
over the world. OBJECTIVES: To assess clinical efficacy and cost-effectiveness of
additional immunotherapy in neonates with severe infections in neonatal inten-
sive care unit (NICU). METHODS: We observed 375 neonates (gestational age (GA)
25-41 weeks) with severe early-onset infections in NICU. Fifty-two neonates with
hypogammaglobulinemia were treated with normal human immunoglobulin
(NHI), 85 newborn infants with lymphopenia were treated with human interleukin
2 (HI2), 94 neonates with low mitogen-induced interferon- production treated
with interferon-2b. A total of 144 were under standard treatment without addi-
tional immunotherapy. RESULTS: Administration of NHI resulted in reduction of
NICU length of stay and mortality level in cases of septic shock - 7.1% [0.2%; 34%] vs
40% in a similar group without immunosubstitutive therapy (p0.05). Administra-
tion of interferon-2b reduces hospital length of stay and mortality rates (g0.009,
OR  0.21 [0.05; 0.67], RR  0.26 [0.07; 0.69], NNT8 [4; 29]). Administration of HI2
reduces NICU length of stay and mortality rates from severe infection (g0.047;
OR0.36 [0.13; 0.98]; RR0.41 [0.17; 0.98]; NNT9 [4; 214]). Administration of immu-
notherapy in early-onset neonatal infections leads to substantial cost savings up to
€ 168,896 per patient in case of NHI treatment, € 60,910 per patient in case of HI2
treatment and € 69, 247 per patient in case of interferon-2b administration.
CONCLUSIONS: Additional immunotherapy in early-onset neonatal infections is a
cost-effective intervention that allows to reduce mortality rates and save money.
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OBJECTIVES: To investigate the cost effectiveness of intermittent treatment of
PMDD (premenstrual dysphoric disorder) with Premalex (escitalopram) 20 mg com-
pared with sertraline 50-100 mg based upon the Clinical Global Impressions – Se-
verity (CGI-S), from a societal perspective. METHODS: We identified one ran-
domised placebo controlled trial with sertraline and one with Premalex, reporting
the CGI-S as an outcome. Using placebo, the CGI-S was used to make an indirect
effect comparison between Premalex and sertraline. The CGI-S was translated into
QALY weights, through the proportion of time spent with a high degree of the
anxiety/depression in the EQ-5D. Costs of health care visits were estimated using a
local treatment pattern survey among GPs and gynaecologists. Official drug prices
were used. A Premalex dose of 15 mg, the average of 10 and 20 mg, was assumed as
it is stated in the SPC text that many of the patients will benefit from 10 mg. 37-75%
lower drug costs were used in years 2-3 due to expected generic competition.
Indirect costs were estimated using a published international study of the effect of
PMDD on sick leave and productivity. A societal perspective was taken over a 3-year
time frame. RESULTS:During the first year, Premalex treatment increased drug costs
(SEK 1599), partly offset by indirect costs saving (SEK 1413), resulting in a total cost of
SEK 186, compared to sertraline. An estimated gain of 0.0044 QALYs with Premalex
compared to sertraline gave an incremental cost per QALY gained of SEK 42200 (EUR
4700). In the next 2 years, drug costs were more than offset by indirect costs saving,
leading to an overall gain of 0.0132 QALYs and a savings of SEK 1600 per three years
with Premalex compared to sertraline.CONCLUSIONS: Treatment of PMDD with Pre-
malex is cost effective compared to sertraline, from a societal perspective.
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OBJECTIVES:A very recent Meta-Analysis shows that the addition of Omega-3 fatty
acid in standard Total Parenteral Nutrition (TPN) is associated with reductions in
infection rate, ICU, and overall lengths of stay (LOSs) for both Intensive Care Unit
(ICU) and elective surgery patients. Aim of this study is the CE analysis of its use in
these patient populations, as compared to standard lipid emulsions. METHODS:
Within a Discrete Event Simulation (DES) scheme, a patient-level simulation model
was developed, with the inclusion of baseline outcomes rates from the Italian ICU
patient population and from published literature; comparative efficacy data for
standard and Omega-3 fatty acids-based regimens from the meta-analysis of pub-
lished randomized clinical trials (conducted on 23 studies with a total of 1502
patients), and country-specific cost data. Clinical outcomes included in the model
are death rates, nosocomial infection rates, and ICU/hospital LOSs. Costs are re-
ferred to Italian, French German and UK health care systems. Probabilistic and
deterministic sensitivity analyses are undertaken to test results’ reliability.
RESULTS:Omega-3 fat emulsions emerged as more effective on average than stan-
dard TPN both in ICU and in non-ICU patients: in all the four national contexts here
considered, reduced mortality rates, infection rates, and overall LOSs yield a lower
total cost per patient. Treatment costs are completely offset by the reduction in
hospital stay costs and antibiotic costs. Sensitivity analyses confirmed the robust-
ness of these findings. CONCLUSIONS: These results indicate that the addition of
Omega-3 to standard TPN is expected to improve clinical outcomes and concur-
rently give a saving for Italian, French, German and UK hospitals.
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OBJECTIVES: LNG-IUS 12 is a novel intrauterine contraceptive system for up to 3
years use with an average in vitro release rate of 12g of levonorgestrel per day.
This study was conducted to estimate the relative cost-effectiveness of LNG-IUS 12
versus short-acting reversible contraception (SARC) in the United States from a
third-party payer’s perspective. METHODS: A Markov model was constructed to
compare the effectiveness and costs of LNG-IUS 12 and SARC over a 3-year period
in a cohort of 1000 women aged 20 to 29 years, the age group in which most
unplanned pregnancies occur. SARC methods comprise contraceptives commonly
used by this age cohort, including oral contraceptives, the ring, the patch and
injections. Primary health states included initial/continued use of contraceptive
method and method failure (unplanned pregnancies). The impact of switching
methods was also incorporated into the model and tested through sensitivity anal-
ysis. Estimates for probabilities of failure and discontinuation, resource utilization
and costs were derived from a comprehensive literature review, average wholesale
drug prices and the 2012 Medicare Reimbursement Fee Schedule, respectively. Cost
and effectiveness metrics for SARC were calculated as weighted averages using
distribution of use data for SARC. One-way sensitivity analyses were performed on
all key variables. RESULTS: LNG-IUS 12 dominated SARC in women aged 20 to 29
years, resulting in fewer unplanned pregnancies (9.86 vs. 238.75) and lower total
costs ($930,187USD vs. $1,528,163USD, a 39% saving) over 3 years. The cost of con-
traception and number of unplanned pregnancies associated with SARC were key
model drivers. Results were insensitive to variation in key input values during
one-way sensitivity analyses. CONCLUSIONS: From a third-party payer perspec-
tive, LNG-IUS 12 is a more cost-effective contraceptive option than SARC. Addi-
tional analysis of discontinuation patterns and planned pregnancy events within
future model extensions will help to further reflect real-life utilization pattern.
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OBJECTIVES: To assess clinical efficacy and cost-effectiveness of human recombi-
nant interferon-2b in neonates with intrauterine infections in neonatal intensive
care unit (NICU). METHODS: We observed 151 neonates (gestational age (GA) 25-40
weeks) with severe intrauterine infections in NICU. Group 1 included 94 neonates
with severe intrauterine infections treated with interferon-2b, 150 000 IU per
suppositorium twice a day per rectum during 7 days in addition to combined anti-
bacterial and supportive therapy; group 2 consisted of 57 neonates under standard
treatment without additional immunotherapy. Initially neonates of both groups
were comparable. Effectiveness data were used to populate a decision model to
estimate the cost-effectiveness of interferon-2b and standard therapy. Direct and
indirect costs were measured. Published cost data were applied to assess differ-
ences in treatment costs. RESULTS: Low mitogen-induced interferon- production
(12 pg/ml) was detected in 25% [18%; 33%] of neonates with severe intrauterine
infections, its association with significantly higher incidence of pneumonia
(0.001), necrotizing enterocolitis (0.001) and urinary tract infections (0.026)
was proved. Administration of human recombinant interferon-2b to neonates,
suffering from severe infections, provides improvement of mitogen-induced pro-
duction of interferon-, reduces hospital length of stay and mortality rates
(0.009, OR 0.21 [0.05; 0.67], RR 0.26 [0.07; 0.69], NNT8 [4; 29]). Interferon-2b
administration for severe early-onset neonatal infections decreases direct costs
per patient by 20% (direct costs per patient € 6,802 and € 8,549 for interferon-2b
and control groups, respectively). Interferon-2b administration for intrauterine
infections leads to substantial cost savings (up to € 69,247 per patient).
CONCLUSIONS: Immunotherapy with interferon-2b is a cost-effective interven-
tion improves the clinical course and outcome in case of severe intrauterine infec-
tions.
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OBJECTIVES: Several published studies have demonstrated that the supplementa-
tion of Omegaven® has better clinical outcomes in Systemic Inflammatory Re-
sponse Syndrome (SIRS) or elective major surgery patients treated in Intensive Care
Units (ICUs),with shorter average lengths of stay in hospital and reduced fatality
rate , as compared to standard total parenteral nutrition (TPN) regimens. The ob-
jective of the simulation study was to evaluate the CE of the supplementation of
Omegaven® vs standard TPN in the Chinese setting. METHODS: A discrete event
simulation (DES) model was constructed to compare the nutritional strategies in
elective surgery and SIRS patients, by combining outcomes recorded in 79 elective
major surgical patients and 56 SIRS patients receiving TPN in the surgical ICU of a
tertiary hospital in Shanghai. Omegaven® efficacy estimates from a random effects
Bayesian meta-analysis on Chinese and international clinical trials, and Chinese
cost data collected in the same hospital, comprising ICU and general ward costs,
and the cost for TPN. RESULTS: Omegaven® showed being effective in reducing
fatality rate and total hospital length of stay (- 2.8 and -2.5 days) in both surgical and
SIRS patients. In the SIRS group, the treatment could avoid 5.7 deaths every 100
patients. Reduced hospitalizations costs completely offset treatment cost, with a
saving associated with Omegaven® of about 8,000 and 6,800 RMB in surgical and
SIRS patients, respectively. CONCLUSIONS: The supplementation of Omegaven®
can be considered dominant versus standard TPN, as the results of DES show that
a mean increase of the effectiveness is associated with a mean decrease of the
costs.
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OBJECTIVES: Ulipristal acetate - a selective progesterone receptor modulator - was
proved to be effective for 3 month pre-operative treatment of moderate to severe
symptoms of uterine fibroids in adult women of reproductive age. The aim of this
analysis was to assess the cost-effectiveness of ulipristal acetate 5 mg as an add-on
therapy to standard pre-surgical treatment in Hungary. METHODS: A Markov
state-transition economic model was developed over 10 year time horizon. Ulip-
ristal acetate was compared to 1) pre-surgical observation, and 2) immediate hys-
terectomy. The model comprises mutually exclusive health states: no/mild bleed-
ing disorder, heavy bleeding disorder, persistent heavy bleeding disorder,
myomectomy, post-myomectomy with no/mild bleeding disorder, post-myomec-
tomy with heavy bleeding disorder, hysterectomy, post-hysterectomy, post-meno-
pausa and death. Transition probabilities and utility values were drawn from the
Pearl I clinical trial and scientific literature. Resource utilisation and unit costs were
derived from the consensus panel of clinical experts and National Health Insurance
Fund tariffs and publications. Costs and QALYs were discounted at a yearly rate of
3.5%. RESULTS: Addition of 3 month ulipristal acetate to the standard pre-opera-
tive therapy was predicted to achieve an additional 0.019 QALYs compared to ob-
servation at an estimated incremental cost of €376, resulting an incremental cost of
20,180 €/QALY. Results were most sensitive to the utility value of post-hysterec-
tomy, but robust to changes in further model parameters. When 3 month of ther-
apy was compared to immediate hysterectomy without any observation period,
the ICER was reduced to 6,095 €/QALY. CONCLUSIONS: The analysis suggests that
adding ulipristal acetate treatment to standard pre-surgical therapy represents
good value for money according to currently accepted cost-effectiveness criterion
in Hungary. Inclusion of societal benefits may considerably reduce the cost-effec-
tiveness ratio, however further evidence from observational studies is needed to
capture potential benefits of ulipristal acetate therapy on fertility.
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OBJECTIVES: Testosterone replacement therapy (TRT) is recommended for the
treatment of primary and secondary hypogonadism. However, long-term implica-
tions of this therapy have not been investigated extensively. Therefore, the aim of
this analysis was to evaluate health outcomes and costs associated with life-long
TRT in patients suffering from Klinefelter syndrome and late-onset hypogonadism
(LOH). METHODS: A Markov model was developed to assess cost-effectiveness of
testosterone undecanoate (TU) depot injection treatment compared with no treat-
ment. Health outcomes and associated costs were modeled in monthly cycles per
each patient individually along life-time horizon. Modeled health scenarios in-
cluded development of type 2 diabetes, depression, cardiovascular and cerebrovas-
cular complications and fractures. Results were expressed in terms of incremental
quality of life years (QALY) gained, incremental costs and incremental cost-effec-
tiveness ratio (ICER). Analysis was performed for the Swedish health care settings
from health care payer’s and societal perspective. One way sensitivity analyses
served to evaluate robustness of the results. RESULTS: TU depot injection in
Klinefelter population yielded a gain of 1.67 QALYs compared to the no-treatment
at an incremental cost of 257,757 SEK (28,176 EUR), showing an ICER of 154,459 SEK
(16,884 EUR) per QALY gained. Outcomes in LOH population estimated benefits of
TRT at 180,400 SEK (19,719 EUR) per QALY gained. Results showed to be consider-
ably robust when tested in sensitivity analysis. Variation of relative risk to develop
type 2 diabetes had the highest impact on long-term outcomes in both patient
groups. CONCLUSIONS: TRT treatment proved its efficacy across many clinical
trials. This analysis suggests that life-long TU depot injection therapy is cost-effec-
tive in Sweden for patients with hypogonadism. Hence, it can support clinicians in
decision making when considering appropriate treatment strategies for patients
with testosterone deficiency.
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OBJECTIVES: The assessment of indirect costs represents an extremely important
issue when managing chronic diseases. Patients’ lost productivity is often over-
looked by decison makers, although it is fundamental for the complete estimation
of the true economic impact of disease. The objective of this study is to estimate the
social savings obtained with Adalimumab compared to standard therapies for the
treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis,
Crohn’s disease and psoriasis, in the Italian population. METHODS: Five different
economic models have been developed to estimate the cost utility of Adalimumab
vs standard care for each of the diseases (the economic models were developed by
external consultants). Both Italian National Health System (direct costs) and social
(direct costs loss of productivity) perspectives were adopted. For each pathology
models have calculated the loss of productivity per pt/year with standard therapy
and with Adalimumab. A sensitivity analysis, based on the variability of model
parameters, was performed in order to assess the robustness of the results.
RESULTS: In the base case scenario, the average annual social cost (weighted for
prevalence of eligible patients for biologic treatment of each pathology) per patient
amounted to €1274,25 if treated with standard care, compared with €569,48 if
treated with Adalimumab. Adalimumab treatment would allow –9,4% (€42 mil-
lions) reduction of the total social cost assuming 17% of market penetration for
patients eligible for biologic use. Sensitivity analysis shows that annual saving in
social costs can vary from 8,1 to 11,9% assuming an average market share of 17% of
Adalimumab. CONCLUSIONS: Adalimumab has a significant impact in reducing
social costs for all the diseases considered in this study. These aspects, often ne-
glected in decision makers’ assessments, should instead be included in the overall
evaluation of benefits, of innovative technologies as biologic drugs.
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OBJECTIVES: Parenteral nutrition (PN) is critical in neonatal and pediatric care for
patients unable to tolerate enteral feeding. Considering the limited cost data on
pediatric PN in Belgium, the aim of this study was to evaluate total Belgian PN costs
when admixtures are produced in-hospital, either in a pharmacy or in the ward.
METHODS: A cost-model was used to assess the following: nutrient costs; labor
costs (personnel costs to prescribe and prepare); disposable costs (supplies used);
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